Sam-A Pharm삼아제약
009300 · KOSDAQ · ₩009300 · 삼아제약
₩13,630▼ ₩20 (0.15%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 56.2% | 59.6% | 63.6% | 63.4% | 61.4% | 59.7% |
| Operating margin | 7.6% | 14.1% | 25.6% | 24.2% | 22.3% | 11.1% |
| Net margin | 14.6% | 16.6% | 23.1% | 22.0% | 14.6% | 6.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −7.1% | −18.6% | −1.7% | +19.0% | +49.5% | — |
| Operating income growth | −50.1% | −55.1% | +4.1% | +28.7% | +201.8% | — |
| Net income growth | −18.5% | −41.4% | +3.3% | +79.4% | +251.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 4.6% | 5.8% | 10.5% | 11.2% | 6.8% | 2.0% |
| Return on assets | 4.2% | 5.2% | 9.2% | 9.8% | 6.1% | 1.8% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 8.8% | 8.3% | 13.1% | 15.4% | 12.5% | 10.0% |
| Net debt to equity | −33.4% | −36.3% | −23.1% | −32.9% | −5.1% | −4.6% |
| Current ratio | 1,010.8% | 978.1% | 551.4% | 558.0% | 542.1% | 564.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Sam-A Pharm / 삼아제약 / 009300 / KRX:009300
Source: KRX statistical information